Novartis

Novartis

Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Medicine Aug 31
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide Diskus.   Study highlights importance of improving treatment "persistence" over time for long-term respiratory diseases.
Medicine Aug 30

Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine -   Erelzi is approved for all indications included in the reference prod

Medicine Aug 25

The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression

Medicine Aug 3

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer Designation underscores the continuing un

Medicine Aug 29

13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business -   Interactive pro

Medicine Aug 15

The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is acquired in the thymus.

Medicine Aug 2

US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma -   The CyPass Micro-Stent is designed t



website preview

Link

Medicine and Life Sciences